A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma

This study is particularly looking for adults aged 18 or over who have been diagnosed with multiple myeloma. The study is divided into several groups, each with different requirements based on your past treatments and how your condition has progressed.

For example, some groups are for people who have already had certain treatments, like a proteasome inhibitor (PI) and an IMiD (immunomodulatory therapy), and whose cancer hasn't responded well to lenalidomide. Other groups are for those whose cancer returned within a year after a stem cell transplant or a year after starting their first anti-myeloma treatment. There are also specific groups for people who have received a particular set of treatments including an anti-CD38 antibody and another type of therapy that targets BCMA.

Some parts of this study are even looking at people who are newly diagnosed with multiple myeloma, either after they've had some initial intensive treatment, or if they have certain features that classify their cancer as 'high risk'. The doctors running the study will carefully check all your medical history to see if you meet the specific criteria for any of the study groups.

If you join this study, you would receive the investigational cell therapy called JNJ-68284528. Depending on which group you're in, you might also receive other standard treatments for multiple myeloma, such as lenalidomide, daratumumab, bortezomib, or dexamethasone, either before or after the main study treatment. Taking part will involve regular visits to the hospital or clinic for check-ups, blood tests, and scans to monitor your health and how you're responding to the treatment. This is to make sure the treatment is safe and working as expected. They will also be looking closely for any remaining cancer cells. The total duration of your involvement could vary depending on the study group and your response, but these types of studies often involve an initial treatment period followed by a longer period of follow-up visits to track your progress.